Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2024Lung CancerOpen Access

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

View Full Paper
Ask AI
Bookmark
Share

Authors

BCByoung Chul ChoJHJi‐Youn HanKLKi Hyeong Lee

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cho et al. (2024) studied this question.

synapsesocial.com/papers/68e785c1b6db6435876f88cdhttps://doi.org/10.1016/j.lungcan.2024.107509
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC2019 · 2,937 citations
  2. 2A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)2014 · 1,593 citations
  3. 3Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER3012023 · 17 citations
  4. 4Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer2019 · 93 citations
  5. 5Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin2021 · 137 citations